NoV GI.1/GII.4 Bivalent VLP Vaccine
NOR-210
Phase 2 mab completed
Quick answer
NoV GI.1/GII.4 Bivalent VLP Vaccine for Norovirus is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Norovirus
- Phase
- Phase 2
- Modality
- mab
- Status
- completed